Beacon Therapeutics was launched in 2023 by Syncona as a gene therapy biotech company whose purpose is to improve or restore vision in patients with various retinal diseases that eventually lead to blindness. They use a target generation technology platform to identify and screen new therapeutic targets. The foundation of Beacon Therapeutics originates from co-founder Dr. Robert MacLaren’s ground-breaking work in ophthalmology at the University of Oxford.

Beacon Therapeutics

Senior Clinical Scientist - Remote

Beacon Therapeutics’ AGTC-501 holds potential to become first gene therapy in XLRP space: GlobalData - Express Pharma

Retinitis Pigmentosa Treatment Market 2034: Clinical Trials, Epidemiology, Medication, FDA, EMA, PDMA Approvals, Pipeline and Companies by DelveInsight - The Globe and Mail

XLRP Clinical Trials

We are looking forward to the American Academy of Ophthalmology's  Annual Meeting in Chicago this week! Please reach out or stop by Booth 1938 to connect with our team representing Beacon at the meeting. Lance Baldo, Darin Curtiss, Amy Christenson, Amy Adelman House, Ashley Simmons, Benjamin Rice, DO, Marianne Torontali, Ben Novak, Amy Goker, Cheryl Reburiano, JungAh Jung, Rachael Wagner, PhD, Micaela Nee.

To learn more about the work we are doing at Beacon to bring transformative ocular gene therapies to patients, please visit https://www.beacontx.com/

#AAO2024 #genetherapy #ophthalmology 

 Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies 

 Beacon Therapeutics: Ophthalmic Gene Therapy Company Raises $170 Million 

Beacon Therapeutics is attending the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in La Nuvola, Rome October 22-25. Please reach out to connect with our team members representing Beacon at the meeting. Azadeh Kia, Paniz Tayaranian Hosseini and Will Crisp. 

#ESGCT2024 #genetherapy

Ascend Acquires Florida Facility and Expertise, Bolstering Gene Therapy Development - Contract Pharma

Beacon raises $170m to propel eye disease gene therapy - BioProcess Insider



                            
                            

                                
                            

                            

                                Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer

                                
                                    
                                        
                                            24 July 2024                                                                                    

                                                                            

                                
                            

                        

Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP) - PR Newswire



                            
                            

                                
                            

                            

                                Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP)

                                
                                    
                                        
                                            6 December 2024                                                                                    

                                                                            

                                
                            

                        

 Beacon attracts $170M series B to push eye disease gene therapy through late-stage trial 

At First Sight - The Medicine Maker

Chutes & Ladders—Moderna co-founder Robert Langer leaves board as David Rubenstein joins - Fierce Biotech



                            
                            

                                
                            

                            

                                Beacon Therapeutics Launch

                                
                                    
                                        
                                            12 June 2023                                                                                    

                                                                            

                                
                            

                        



                            
                            

                                
                            

                            

                                Beacon Therapeutics Treats First Patient in VISTA Registrational Trial for laru-zova (AGTC-501)

                                
                                    
                                        
                                            12 June 2024                                                                                    

                                                                            

                                
                            

                        

 Beacon Therapeutics shares 12-Month Data from Phase 2 SKYLINE trial of AGTC-501 for patients with XLRP 

 Beacon Therapeutics launches with $120M to develop gene therapies for retinal diseases 

AAV safety and potency: exploring the analytical maze of gene therapy - Nature.com



                            
                            

                                
                            

                            

                                Beacon Therapeutics Announces Positive 12-Month Data from Phase 2 SKYLINE Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa

                                
                                    
                                        
                                            8 February 2024                                                                                    

                                                                            

                                
                            

                        

Alachua-based biotech company invests millions in genetic blindness disease research - WCJB

I am a patient/caregiver

Advanced therapy CDMO Ascend nabs Florida manufacturing site and team from ocular gene therapy outfit Beacon - FiercePharma

Beacon will be attending Advanced Therapies USA in Philadelphia this week! 

Please reach out if you want to connect with our team there. Tom Biancardi Amy Adelman House Darin Curtiss Amy Christenson Tristan Martin

#adtherapiesUSA #advancedtherapies #genetherapy

Ascend continues to climb with deal that elevates the CDMO’s US footprint - FiercePharma

Syncona portfolio company, Beacon Therapeutics, today announced the presentation of three-month data from the Phase II DAWN trial of its lead asset, laru-zova (AGTC-501). 

The data support the ongoing development of laru-zova in XLRP, a severe, aggressive, inherited retinal disease. With no treatment options available, XLRP impacts boys and young men and often leads to blindness by middle age.

Read the full release here: https://lnkd.in/egZrDRsN

#lifesciences #biotech #ophthalmology

Beacon Therapeutics raises $170M in series B to advance gene therapies for eye disease - BioPharma-Reporter.com

 AiViva Biopharma Appoints Lester J. Kaplan, PhD to the ... 


			

Beacon attracts $170M series B to push eye disease gene therapy through late-stage trial - Fierce Biotech

 Beacon lights up with $170m for retinal disease gene therapy 

 4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity 

 The Future of Vision with Gene Therapy for Retinal Health 

Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies - PR Newswire

Beacon launches with $121M and late-stage eye disease asset - BioWorld Online

Launch of Beacon Therapeutics with focus on gene therapies for retinal diseases - BioWorld Online



                            
                            

                                
                            

                            

                                Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of laru-zova (AGTC-501) in Patients with XLRP

                                
                                    
                                        
                                            19 September 2024                                                                                    

                                                                            

                                
                            

                        

 Beacon Therapeutics Raises $170M in Series B Funding 

Market news - Research the market

 Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP) 

We are very pleased to welcome another new executive team member to the Beacon team. Welcome Natasha Jarrett, who joins us as SVP Regulatory Affairs! 

Built from biotech parts, Beacon launches with $120M to develop eye gene therapies - BioPharma Dive

 Beacon Therapeutics Raises $120M in Funding 

Gene Therapy & IRDs

Trimarchi becomes president, COO of BridgeBio - BioCentury

 Faster than light drug discovery: Superluminal launches with ... 

We hope to see you at the European Society of Retina Specialists (EURETINA)  Annual Meeting in Barcelona this week, where Paul Yang, MD, PhD, Chief, Paul H. Casey Ophthalmic Genetics Division, Casey Eye Institute (OHSU), is presenting 36-Month Interim Results from the Beacon Therapeutics’ Phase 1/2 HORIZON Study on September 19, 15:30 - 15:36 CEST. Thank you to Dr. Yang and to our team representing Beacon at EURETINA. Dr. Lance Baldo, Darin Curtiss, Ashley Simmons, Benjamin Rice, DO, Kathryn Burns, MHA, Amy Perniciaro and Doug Leonard. 

Please visit https://www.beacontx.com/ to see the presentation and learn more about the work we are doing at Beacon. 

#EURETINA24 #genetherapy #ophthalmology #retina

According to data presented at #FLORetina:

Laru-zova demonstrated positive safety and early efficacy in improving low luminance #visualacuity in patients with X-linked #retinitispigmentosa.

Lead author Prof. Paulo Eduardo Stanga, MD, spoke with Healio🔗
#OcularSurgeryNews #Ophthalmology
https://lnkd.in/eqjdvsGJ

 Syncona's Beacon Therapeutics presents trial results at conference 

Learn more at beacontx.com

 Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer 

Syncona launches new gene therapy company Beacon Therapeutics - European Biotechnology News

Beacon Therapeutics spun out by Syncona and Oxford raises £96 million for retinal gene therapy - University of Oxford

Resources



                            
                            

                                
                            

                            

                                Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona’s Patented AAV204 Capsid for Select Ophthalmology Indications

                                
                                    
                                        
                                            11 July 2024                                                                                    

                                                                            

                                
                            

                        

 QuotedData’s morning briefing 9 December 2024 – JEDT, BBH, OIG, SYNC 

Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa - StreetInsider.com



                            
                            

                                
                            

                            

                                Ascend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV production

                                
                                    
                                        
                                            9 April 2024                                                                                    

                                                                            

                                
                            

                        

Beacon Therapeutics Treats First Patient in VISTA Registrational Trial for AGTC-501 - PR Newswire

 Retinitis Pigmentosa Market to Grow Rapidly at a CAGR of 16.8% by 2034 | DelveInsight 

Beacon Therapeutics Announces Positive 12-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa - PR Newswire



                            
                            

                                
                            

                            

                                Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa

                                
                                    
                                        
                                            15 October 2024                                                                                    

                                                                            

                                
                            

                        

 Beacon Therapeutics to evaluate Abeona’s AAV204 capsid for ophthalmology indications 

 Syncona portfolio company Beacon Therapeutics raises $170 million in a Series B financing 

 Look sharp: Tenpoint Therapeutics closes $70M series A ... 

 The Week’s 10 Biggest Funding Rounds: Madhive Tops In Very Slow Week 


              Beacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP) - Beacon Therapeutics
            

Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP - PR Newswire

Beacon of Light: Retinal Gene Therapy Developer Launches with $120M - Genetic Engineering & Biotechnology News

Beacon Therapeutics will present at the Ophthalmology Futures Retina Forum 2024 in Barcelona on September 18th. You can see our CEO, Lance Baldo, MD and learn more about the work we are doing at Beacon to bring transformative ocular gene therapies to patients. You can also connect with Lance and the Beacon team at the European Society of Retina Specialists (EURETINA) meeting in Barcelona this week. 

#genetherapy #EURetina24 #retina #ophthalmology

Beacon Therapeutics - The Pharma Letter


              Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa - Beacon Therapeutics
            

 Beacon Therapeutics lands $170M for eye gene therapies 

Beacon raises $170M to take on J&J in ocular gene therapy - Endpoints News

 Ascend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon ... 

 Beacon Therapeutics Treats First Patient in VISTA Registrational Trial for AGTC-501 

Genetic Testing

I am a healthcare provider

Beacon Therapeutics launches with £96 million ($120 - GlobeNewswire

Beacon Therapeutics Appoints New CEO and CFO - Contract Pharma

Syncona launches new gene therapy company Beacon Therapeutics - BioPharma-Reporter.com

 Inherited Retinal Disease Market Size and Share to Grow by 2034, Assesses DelveInsight | Key Companies - Spark ... 

Ascend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV production - PR Newswire

 Beacon's AGTC-501 to challenge Spark's Luxturna in retinitis market 

 Promising Gene Therapy for X-linked Retinitis Pigmentosa: Beacon Therapeutics' AGTC-501 Shows Positive Results 

 Beacon Therapeutics Announces Positive 12-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X ... 

Ascend takes Beacon’s manufacturing assets; 89bio’s $135M build in China - Endpoints News

Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer - PR Newswire



                            
                            

                                
                            

                            

                                Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies

                                
                                    
                                        
                                            3 July 2024                                                                                    

                                                                            

                                
                            

                        

Beacon Therapeutics

Business:

About: